Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JUV001
- Development stage
- Preclinical
- Lead developer
- FoxBio
- Modality
- Small Molecules
- Administration
- Subcutaneous
01
Overview
JUV001 is a small molecule senolytic drug under development by FoxBio, a joint venture formed by Juvenescence and Antoxerene. It is being developed for the treatment of osteoarthritis. The drug's mechanism of action involves targeting the FOXO4-p53 interaction to selectively destroy senescent cells, which are implicated in various age-related diseases.
02
Targets
FOXO3 (Forkhead box protein O3)
Beyond the preview
Go deeper on JUV001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JUV001.